DAX23.600 -0,9%Est505.873 -0,9%MSCI World4.343 -0,1%Top 10 Crypto9,2500 -0,7%Nas22.949 +0,2%Bitcoin61.048 +0,8%Euro1,1706 +0,2%Öl99,52 +5,6%Gold4.729 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Deutsche Telekom 555750 Lufthansa 823212 SAP 716460 Siemens Energy ENER6Y BASF BASF11 NVIDIA 918422 Mercedes-Benz Group (ex Daimler) 710000 Microsoft 870747 Allianz 840400 Amazon 906866 BioNTech (ADRs) A2PSR2 DroneShield A2DMAA Deutsche Bank 514000 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Iran-Gespräche gescheitert: DAX fällt -- Dow startet leichter -- Entlastung bei Benzinpreisen kommt -- Nike, Palantir, DroneShield, TUI, Telekom, VW, Rüstungsaktien, BioNTech, Lufthansa im Fokus
Top News
Öl: Ende der Fahnenstange? Öl: Ende der Fahnenstange?
Nike-Aktie unter Druck: Experten werden vorsichtiger - Analyst halbiert Kursziel Nike-Aktie unter Druck: Experten werden vorsichtiger - Analyst halbiert Kursziel
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

IDEAYA Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
29,39 EUR +3,48 EUR +13,43 %
STU
31,92 EUR +2,17 EUR +7,29 %
HAML
finanzen.net zero
IDEAYA Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.2,29 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PJPB

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45166A1025

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIDYA

IDEAYA Biosciences Aktien News

DatumMeistgelesen
PR NewswireIDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
PR NewswireIDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
PR NewswireIDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uve...
Wer­bungIDEAYA Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireIDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
PR NewswireIDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
PR NewswireIDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for M...
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
PR NewswireIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
PR NewswireIDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on...
PR NewswireIDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
PR NewswireIDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
PR NewswireServier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
PR NewswireIDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Resea...
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
PR NewswireIDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
PR NewswireIDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
PR NewswireIDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
PR NewswireIDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
PR NewswireIDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
PR NewswireIDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
PR NewswireIDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

IDEAYA Biosciences News

IDEAYA Biosciences News: auf dieser Seite finden Sie alle IDEAYA Biosciences News und Nachrichten zur IDEAYA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch IDEAYA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um IDEAYA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.